Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421838 | 0.98 | AKR1C1 (0.68) | AKR1C1HSD11B1APPCYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL28577324 | 0.96 | AKR1C1 (0.66) | AKR1C1HSD11B1APPCYP3A4CYP2C9 | |
| SCHEMBL988946 | 0.94 | AKR1C1 (0.62) | AKR1C1HSD11B1APPCYP3A4CYP2C9 | |
| SCHEMBL301150 | 0.90 | APP (0.61) | AKR1C1HSD11B1APPCYP3A4CYP2C9 | |
| SCHEMBL11044295 | 0.83 | HSD11B1 (0.52) | AKR1C1HSD11B1HDAC1HDAC4ALDH1A1 | |
| SCHEMBL3842811 | 0.83 | LMNA (0.55) | AKR1C1HSD11B1MEN1KMT2AHDAC1 | |
| SCHEMBL4809604 | 0.83 | HSD11B1 (0.51) | AKR1C1HSD11B1HDAC1HDAC4ALDH1A1 | |
| SCHEMBL1128270 | 0.82 | AKR1C1 (0.68) | AKR1C1HSD11B1APPCYP3A4CYP2C9 | |
| SCHEMBL19249602 | 0.82 | AKR1C1 (0.96) | AKR1C1HSD11B1MEN1KMT2ATSHR | |
| SCHEMBL66387 | 0.82 | AKR1C1 (0.96) | AKR1C1HSD11B1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| CN-101394847-B | Cycloalkylamines as monoamine reuptake inhibitors | 塞普拉柯公司 | 2017-05-24 | — | — | CN | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102686571-B | tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2015-05-07 | — | — | US | disclosed |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | ICAGEN, INC. | 2004-04-15 | — | — | US | disclosed |
| US-20040073036-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-6699866-B2 | FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS | SEPRACOR INC. | 2004-03-02 | — | — | US | disclosed |
| WO-2004004714-A1 | SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003063797-A2 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002083863-A2 | THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF | SEPRACOR, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0272580-A2 | Liquidcrystalline cyclohexylbenzene derivatives their manufacturing and novel nematic admixtures containing same | Wojskowa Akademia Techniczna im. Jaroslawa Dabrowskiego (PL) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | AKR1C1 3418/4885HSD11B1 919/4885APP 489/4885 |
| US-20040073036-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | AKR1C1 701/4885HSD11B1 1080/4885APP 3296/4885 |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | AKR1C1 2520/4885HSD11B1 1340/4885APP 432/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | AKR1C1 3418/4885HSD11B1 919/4885APP 489/4885 |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | KCNN1, KCNN2, KCNH2 | AKR1C1 1699/4885HSD11B1 4164/4885APP 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.